Aidoc, a startup that developed foundation-model-powered clinical AI solutions, landed a $150 million funding round, less than a year after raising the same nine-figure amount in new financing.
The series E round was led by Growth Equity at Goldman Sachs Alternatives, with participation from General Catalyst, SoftBank Vision Fund 2 and NVentures—Nvidia's venture capital arm.
The round brings the company's total funding to over $500 million, less than a year after a growth round led by General Catalyst and Square Peg. Aidoc executives noted that this underscores the pace of the startup's momentum and the "accelerating demand for enterprise-scale clinical AI."
Diagnostic errors and delays contribute to at least 400,000 deaths each year in the United States, driven by rising imaging volumes, workforce shortages and growing clinical complexity.
Aidoc, founded in 2016, provides AI-powered tools in radiology, cardiology, neurovascular and vascular and plans to expand into oncology.
Hospitals are now seeking broader, system-wide solutions and clinical AI that can be deployed across entire health systems.
Aidoc developed a clinical foundation model, called CARE (Clinical AI Reasoning Engine), that assists physicians in clinical decisions. Earlier this year, CARE received its first FDA clearance for a comprehensive, double-digit foundation model-based triage system for clinical imaging. The company analyzes more than 60 million patient cases annually and is deployed across nearly 2,000 hospitals.
Aidoc also developed an enterprise AI platform, Aidoc aiOS, that embeds AI directly into clinical workflows, enabling health systems to deploy, manage and scale multiple FDA-cleared solutions through a centralized operating layer.
“By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error,” Elad Walach, co-founder and CEO of Aidoc, said in a statement. “We feel a deep responsibility to deploy CARE safely and at scale across health systems. This funding accelerates comprehensive disease coverage and advances end-to-end AI across CT and X-ray, spanning the full workflow, including pixel to draft report within two years.”
With the fresh capital, Aidoc plans to scale its CARE foundation model and expand into additional clinical indications. "Comprehensive coverage of all key clinically significant conditions in CT and X-ray, across the body, both acute and chronic—automatic detection, measurement, comparison and more," Walach told Fierce Healthcare.
Last year, the company expanded its clinical AI solutions into oncology and cardiovascular disease to aid clinicians with decision-making and diagnosis. It also secured FDA clearance for its CADt AI solution back in February 2025. That clearance applied to Aidoc's rib fractures triage solution.
The company also plans to build out new capabilities, such as automated imaging draft report creation to power end-to-end clinical AI workflows.
As clinical AI moves to enterprise deployment, hospitals are looking to consolidate standalone tools under centralized operating frameworks to more efficiently manage and govern AI at scale, and that trend will drive adoption of the company's aiOS enterprise AI platform, according to executives.
Scaling AI technology in complex health systems also requires oversight and accountability to operate safely in real-world care.
“Aidoc pairs advanced technology with regulatory rigor in a way that few companies have achieved,” Christian Resch, partner at Growth Equity at Goldman Sachs Alternatives, said in a statement. “Health systems consistently describe tangible results, including improved radiology efficiency, shorter lengths of stay, and measurable financial returns. We believe this combination of innovation, safety, technical rigor, and operational discipline positions Aidoc as a long-term leader in clinical AI.”
Aidoc raised a $150 million growth round in July 2025 and banked a $110 million series D round in 2022, followed by a $30 million growth round in 2023. The company also raised $66 million in series C funding in 2021. Previous funding rounds include a $27 million series B round in 2019, followed by $47 million in 2020.